Sunday, September 27
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on the blockbuster weight-loss drugs expire next year.The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some emerging markets, its managing director, Siddharth Mittal, told Bloomberg News. “I would say that we have the best chance in Canada” to start launching off-patent semaglutide, he said. “If everything goes seamlessly,” then Biocon can receive an approval to sell sometime in 2026, Mittal added.The Kiran Mazumdar Shaw-led insulin maker is joining the leagues of the world’s largest generic drugmakers, which inclu
The Wisconsin Supreme Court's liberal majority struck down the state's 176-year-old abortion ban on Wednesday, ruling 4-3 that it was superseded by a newer state law that criminalizes abortions only after a fetus can survive outside the womb. State lawmakers adopted the ban in 1849, making it a felony when anyone other than the mother "intentionally destroys the life of an unborn child." It was in effect until 1973, when the U.S. Supreme Court's landmark Roe v. Wade decision legalizing abortion nationwide nullified it. Legislators never officially repealed the ban, however, and conservatives argued that the U.S. Supreme Court's 2022 decision to overturn Roe reactivated it. Wisconsin Attorney General Josh Kaul, a Democrat, filed a lawsuit that year arguing that the ban was trumped by aborti
After months of anticipation and a healthy response from investors, HDB Financial Services is finally set to debut on the stock exchanges on July 2. Backed by HDFC Bank, the non-banking financial company (NBFC) is poised to enter the secondary market amid strong demand and a GMP of Rs 71 – indicating a likely 9.6% listing pop over the issue price of Rs 740 per share.The Rs 12,500 crore IPO, comprising a fresh issue of Rs 2,500 crore and an offer-for-sale of Rs 10,000 crore, closed on June 27 with overwhelming demand. The issue was subscribed 17.65 times overall, led by Qualified Institutional Buyers (QIBs) who subscribed their portion 31.73 times.Despite broader market volatility, investor interest was undeterred. Analysts attribute the enthusiasm to the company’s strong parentage, its
